| The anaplastic lymphoma kinase in the pathogenesis of cancer R Chiarle, C Voena, C Ambrogio, R Piva, G Inghirami Nature Reviews Cancer 8 (1), 11-23, 2008 | 1024 | 2008 |
| Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells P Corradini, C Voena, C Tarella, M Astolfi, M Ladetto, A Palumbo, ... Journal of Clinical Oncology 17 (1), 208-208, 1999 | 309 | 1999 |
| Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer M Bregni, A Dodero, J Peccatori, A Pescarollo, M Bernardi, I Sassi, ... Blood, The Journal of the American Society of Hematology 99 (11), 4234-4236, 2002 | 265 | 2002 |
| Simple and rapid in vivo generation of chromosomal rearrangements using CRISPR/Cas9 technology RB Blasco, E Karaca, C Ambrogio, TC Cheong, E Karayol, VG Minero, ... Cell reports 9 (4), 1219-1227, 2014 | 236 | 2014 |
| Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma P Corradini, M Cavo, H Lokhorst, G Martinelli, C Terragna, I Majolino, ... Blood 102 (5), 1927-1929, 2003 | 232 | 2003 |
| Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell … P Corradini, M Astolfi, C Cherasco, M Ladetto, C Voena, D Caracciolo, ... Blood, The Journal of the American Society of Hematology 89 (2), 724-491, 1997 | 214 | 1997 |
| Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy M Massaia, P Borrione, S Battaglio, S Mariani, E Beggiato, P Napoli, ... Blood, The Journal of the American Society of Hematology 94 (2), 673-683, 1999 | 189 | 1999 |
| Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies P Corradini, C Tarella, A Olivieri, AM Gianni, C Voena, F Zallio, M Ladetto, ... Blood, The Journal of the American Society of Hematology 99 (1), 75-82, 2002 | 187 | 2002 |
| High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting P Corradini, C Voena, M Astolfi, M Ladetto, C Tarella, M Boccadoro, ... Blood 85 (6), 1596-1602, 1995 | 181 | 1995 |
| Mutational activation of N-and K-ras oncogenes in plasma cell dyscrasias P Corradini, M Ladetto, C Voena, A Palumbo, G Inghirami, DM Knowles, ... | 173 | 1993 |
| Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. P Corradini, G Inghirami, M Astolfi, M Ladetto, C Voena, P Ballerini, W Gu, ... Leukemia 8 (5), 758-767, 1994 | 148 | 1994 |
| A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors C Voena, M Ladetto, M Astolfi, D Provan, JG Gribben, M Boccadoro, ... Leukemia 11 (10), 1793-1798, 1997 | 133 | 1997 |
| Evidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)-and IgA-secreting multiple myelomas. P Corradini, M Boccadoro, C Voena, A Pileri The Journal of experimental medicine 178 (3), 1091-1096, 1993 | 131 | 1993 |
| Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells M Compagno, Q Wang, C Pighi, TC Cheong, FL Meng, T Poggio, ... Nature 542 (7642), 489-493, 2017 | 129 | 2017 |
| The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration C Voena, C Conte, C Ambrogio, E Boeri Erba, F Boccalatte, S Mohammed, ... Cancer research 67 (9), 4278-4286, 2007 | 125 | 2007 |
| Liposome-encapsulated doxorubicin reverses drug resistance by inhibiting P-glycoprotein in human cancer cells C Riganti, C Voena, J Kopecka, PA Corsetto, G Montorfano, E Enrico, ... Molecular pharmaceutics 8 (3), 683-700, 2011 | 123 | 2011 |
| Advances in cancer immunology and cancer immunotherapy C Voena, R Chiarle Discovery medicine 21 (114), 125-133, 2016 | 119 | 2016 |
| NPM-ALK oncogenic tyrosine kinase controls T-cell identity by transcriptional regulation and epigenetic silencing in lymphoma cells C Ambrogio, C Martinengo, C Voena, F Tondat, L Riera, PF di Celle, ... Cancer research 69 (22), 8611-8619, 2009 | 112 | 2009 |
| p130Cas mediates the transforming properties of the anaplastic lymphoma kinase C Ambrogio, C Voena, AD Manazza, R Piva, L Riera, L Barberis, C Costa, ... Blood 106 (12), 3907-3916, 2005 | 100 | 2005 |
| Maspin and mammaglobin genes are specific markers for RT-PCR detection of minimal residual disease in patients with breast cancer P Corradini, C Voena, M Astolfi, S Dell’Oro, S Pilotti, G Arrigoni, M Bregni, ... Annals of Oncology 12 (12), 1693-1698, 2001 | 100 | 2001 |
